In other in vivo settings of arthritis, cryopyrin-associated periodic syndrome (CAPS), and type 2 diabetes, tranilast prevented NLRP3-dependent inflammatory effects by directly binding to the NATCH domain of NLRP3 [99]. Here, NLRP3 is linked to cryopyrin-associated periodic syndrome.